Beta Blockers in Congestive Heart Failure

Introduction to Beta Blocker Therapy

The European Society of Cardiology recommends beta blockers as standard, evidence-based therapy for chronic heart failure with reduced ejection fraction, significantly reducing mortality and hospitalizations 1, 2
The American Heart Association suggests that beta blockers are strongly recommended for all patients with chronic heart failure and reduced ejection fraction (LVEF <40%) in NYHA class II-IV, with Class I, Level A evidence 1, 2

Beta blockers reduce mortality by 30% and hospitalizations by 40% in NYHA class II-IV heart failure, according to the European Journal of Heart Failure 4, 5
Specific agents proven to reduce mortality include bisoprolol, carvedilol, and sustained-release metoprolol succinate, as stated by the European Heart Journal 1, 6

The European Society of Cardiology states that true contraindications to beta blockers in heart failure patients are specific clinical conditions, such as asthma bronchiale or severe bronchospastic disease, symptomatic bradycardia or hypotension, and second- or third-degree heart block without a pacemaker 1, 2, 7, 8
The American College of Cardiology recommends that beta blockers should not be initiated during acute decompensated heart failure, but this does not mean they are contraindicated in heart failure generally 1, 2

The European Heart Journal suggests that patients must be on background ACE inhibitor therapy and relatively stable, euvolemic, and compensated before starting beta blockers 1, 2, 8
The European Journal of Heart Failure recommends starting with very low doses and titrating slowly over weeks to months, doubling the dose every 1-2 weeks if the preceding dose was well tolerated 1, 2, 8

The European Society of Cardiology advises monitoring for worsening heart failure symptoms, fluid retention, hypotension, and bradycardia during titration, and adjusting treatment accordingly 1, 2, 8
The American Heart Association suggests that if worsening symptoms occur, first increase diuretics or ACE inhibitor dose, and only temporarily reduce beta blocker if necessary 1, 2, 8

The European Journal of Heart Failure recommends that in patients with chronic obstructive lung disease or asthma history, beta-1 selective agents are preferred and should be initiated at low doses 7, 6
The American College of Cardiology states that diabetic patients may have masked hypoglycemia symptoms, but beta-1 selective agents minimize this risk 7, 6